Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

MLA

Allred DC, et al. “Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women with Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24.” Journal of Clinical Oncology, vol. 30, no. 12, Apr. 2012, pp. 1268–73. EBSCOhost, https://doi.org/10.1200/JCO.2010.34.0141.

APA

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N, Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., Mamounas, E. P., & Julian, T. B. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. Journal of Clinical Oncology, 30(12), 1268–1273. https://doi.org/10.1200/JCO.2010.34.0141

Chicago

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, et al. 2012. “Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women with Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24.” Journal of Clinical Oncology 30 (12): 1268–73. doi:10.1200/JCO.2010.34.0141.